Literature DB >> 12975721

Diabetes mellitus and hypertension: a mandate for intense treatment according to new guidelines.

L Michael Prisant1.   

Abstract

Diabetics without a prior myocardial infarction have the same risk of a future myocardial infarction as nondiabetics with a prior myocardial infarction; however, epidemiologic studies suggest that lower blood pressure treatment goals may have potential benefit for diabetics with hypertension. Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and dihydropyridine calcium antagonists have reduced cardiovascular events in patients with diabetes. Angiotensin receptor blockers with diabetic renal disease have reduced the rate of end-stage renal disease, whereas dihydropyridine calcium antagonists show no benefit. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce overall mortality, cardiovascular events, and the development of the overt nephropathy in high-risk patients with diabetes without advanced renal disease. The blood pressure treatment goal for patients with diabetes without macroalbuminuria is less than 130/80 mm Hg and less than 125/75 mm Hg for patients with diabetes and nephrotic syndrome. To achieve these goals, multiple antihypertensive drugs are required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975721     DOI: 10.1097/00045391-200309000-00009

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  2 in total

1.  Effects of efforts to intensify management on blood pressure control among patients with type 2 diabetes mellitus and hypertension: a pilot study.

Authors:  Ramona S Dejesus; Rajeev Chaudhry; Dorinda J Leutink; Melanie A Hinton; Stephen S Cha; Robert J Stroebel
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

2.  Dual factor pulse pressure: body mass index and outcome in type 2 diabetic subjects on maintenance hemodialysis. A longitudinal study 2003-2006.

Authors:  Lydia Foucan; Kheira Hue; Jocelyn Inamo; Jacqueline Deloumeaux; Anne Blanchet-Deverly; Henry Merault; Jean-Marc Gabriel
Journal:  Vasc Health Risk Manag       Date:  2008
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.